Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...
Nasdaq2d
How to Invest in the Nasdaq-100®
There are multiple ways (such as ETFs, mutual funds, options, futures and annuities) that are accessible for investors at all levels to invest in Nasdaq-100®. With a proven history of high index ...
Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...
ABC News2d
Political News
The president-elect made the announcement on Truth Social on Sunday. ABC News’ MaryAlice Parks discusses President Joe Biden's invitation for President-elect Donald Trump to visit the White ...